What autoantibody tests should become widely available to help scleroderma diagnosis and management?

Arthritis Research and Therapy

Volumn 15, Issue 4, 2013, Pages

  Muro, Yoshinao ^a   Sugiura, Kazumitsu ^a   Akiyama, Masashi ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; AUTOANTIBODY; RPP25 ANTIBODY; UNCLASSIFIED DRUG; RIBONUCLEASE P; RPP25 PROTEIN, HUMAN;

CHEMILUMINESCENCE IMMUNOASSAY; DERMATOMYOSITIS; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; EDITORIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; HUMAN; IMMUNOFLUORESCENCE TEST; IMMUNOPRECIPITATION; PHYSICIAN; PREDICTIVE VALUE; PREVALENCE; PULMONARY HYPERTENSION; RACE DIFFERENCE; RADIOIMMUNOPRECIPITATION; RISK FACTOR; SCLERODERMA; SENSITIVITY AND SPECIFICITY; SEROLOGY; SYSTEMIC SCLEROSIS; TREATMENT INDICATION; IMMUNOLOGY; LUMINESCENCE; PROCEDURES;

AUTOANTIBODIES; HUMANS; LUMINESCENT MEASUREMENTS; RIBONUCLEASE P; SCLERODERMA, SYSTEMIC;

EID: 84880140560     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4241     Document Type: Editorial

References (10)

1. Mahler M, Gascon C, Patel S, Ceribelli A, Fritzler MJ, Swart A, Chan EKL, Satoh M. Rpp25 is a major target of autoantibodies to the Th/To complex as measured by a novel chemiluminescent assay. Arthritis Res Ther 2013, 15:R50. 10.1186/ar4210, 3672760, 23587095.
2. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005, 35:35-42. 10.1016/j.semarthrit.2005.03.005, 16084222.
3. Satoh M, Vazquez-Del Mercardo M, Chan EKL. Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases. Mod Rheumatol 2009, 19:219-228. 10.1007/s10165-009-0155-3, 2876095, 19277826.
4. Van Eenennaam H, Vogelzangs JH, Lugtenberg D, Van Den Hoogen FH, Van Venrooij WJ, Pruijn GJ. Identity of the RNase MRP-and RNase P-associated Th/To autoantigen. Arthritis Rheum 2002, 46:3266-3772. 10.1002/art.10673, 12483731.
5. Ceribelli A, Cavazzana I, Franceschini F, Airo P, Tincani A, Cattaneo R, Pauley BA, Chan EK, Satoh M. Anti-Th/To are common antinucleolar autoantibodies in Italian patients with scleroderma. J Rheumatol 2010, 37:2071-2075. 10.3899/jrheum.100316, 20682663.
6. Krzyszczak ME, Li Y, Ross SJ, Ceribelli A, Chan EK, Bubb MR, Sobel ES, Reeves WH, Satoh M. Gender and ethnicity differences in the prevalence of scleroderma-related autoantibodies. Clin Rheumatol 2011, 30:1333-1339. 10.1007/s10067-011-1751-0, 3629275, 21523365.
7. Meyer O, De Chaisemartin L, Nicaise-Roland P, Cabane J, Tubach F, Dieude P, Hayem G, Palazzo E, Chollet-Martin S, Kahan A, Allanore Y. Anti-RNA polymerase III antibody prevalence and associated clinical manifestations in a large series of French patients with systemic sclerosis: a cross-sectional study. J Rheumatol 2010, 37:125-130. 10.3899/jrheum.090677, 19918031.
8. Petri MH, Satoh M, Martin-Marquez BT, Vargas-Ramirez R, Jara LJ, Saavedra MA, Cruz-Gonzalez C, Andrade-Ortega L, Vera-Lastra OL, Salazar-Paramo M, Prieto-Parra RE, Gonzalez-Lopez L, Gamez-Nava JI, Ramirez-Sanches HU, Chan JY, Ross SJ, Chan EK, Vazquez-Del Mercado M. Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara. Arthritis Res Ther 2013, 15:R48. 10.1186/ar4207, 23557279.
9. Muro Y, Ishikawa A, Sugiura K, Akiyama M. Clinical features of anti-TIF1-α antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-γ or anti-Mi-2 autoantibodies. Rheumatology (Oxford) 2012, 51:1508-1513. 10.1093/rheumatology/kes073, 22539482.
10. Ishikawa A, Muro Y, Sugiura K, Akiyama M. Development of an ELISA for detection of autoantibodies to nuclear matrix protein 2. Rheumatology (Oxford) 2012, 51:1181-1187. 10.1093/rheumatology/kes033, 22427409.